Allergen Immunotherapy

  • Roger W. Fox
  • Richard F. Lockey
Part of the Current Clinical Practice book series (CCP)


Allergen immunotherapy, a series of allergen vaccine injections over a defined period, results in decreased sensitivity or tolerance to inhaled or injected allergens, which can be measured both clinically and immunologically. Vaccine is used to describe the immune-modifying properties of allergen immunotherapy. Such therapy is used to treat allergic rhinitis (hay fever), allergic asthma and stinging-insect hypersensitivity. During the first half of the 20th century, efficacy of allergen immunotherapy was based primarily on clinical observations. However, over the past 40 yr, scientific investigations of numerous allergens and of the complexities of the allergic reaction have revealed the immunological changes required for successful immunotherapy. This chapter reviews inhalant allergen immunotherapy utilized to treat allergic rhinitis and/or allergic asthma. Immunotherapy for stinging-insect hypersensitivity is covered in Chapter 6.


Allergic Rhinitis Pollen Season House Dust Mite Birch Pollen Allergen Immunotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Suggested Reading

  1. Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 1995; 151: 969–974.PubMedGoogle Scholar
  2. Adkinson NK, Eggleston PA, Eney D, et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 1997; 336: 324–331.PubMedCrossRefGoogle Scholar
  3. Lockey RF, Bukantz SC, eds. Allergens and Allergen Immunotherapy, ed. 2, revised and expanded. New York, Marcel Dekker, 1999.Google Scholar
  4. Bousquet J, Michel FB. Specific immunotherapy in asthma: Is it effective? J Allergy Clin Immunol 1994; 94: 1–11.PubMedCrossRefGoogle Scholar
  5. Bousquet J, Michel FB. Specific immunotherapy in allergic rhinitis and asthma. In: Busse WW, Holgate ST, eds. Rhinitis and Asthma. Boston, Blackwell Scientific, 1994, 1309–1324.Google Scholar
  6. Bousquet J, Hejjaoui A, Dhivert H, Clauzel AM, Michel FB. Immunotherapy with the standardized Dermatophagoideds pteronyssinus extract. III. Systemic reactions during the rush protocol in patients suffering from asthma. J Allergy Clin Immunol 1989; 83: 797–802.PubMedCrossRefGoogle Scholar
  7. Bousquet J, Lockey RR, Malling HJ, eds. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Geneva: January 27–29 1997. Allergy 1997;53(44 Suppl):1–42.Google Scholar
  8. Bosquet J, Lockey RR, Mailing HJ. Allergy immunotherpy: Therapeutic vaccines for allergic diseases. WHO position paper. JAllergy Clin Immunol 1998; 102: 558–562.CrossRefGoogle Scholar
  9. Bush RK, Ritter MW. Allergen immunotherapy for the allergic patient. Immunol Allergy Clin North Am 1992; 12: 107–124.Google Scholar
  10. Creticos PS, Reed CE, Norman PS and subcenter investigators of the NIAID study. The NIAID cooperative study of the role of immunotherapy in seasonal ragweed-induced adult asthma. JAllergy Clin Immunol 1993; 91: 226.Google Scholar
  11. Creticos PS, Reed CE, Norman PS, Khoury J, Adkinson NF Jr, Buncher CR, Busse WW, Bush RK, Gadde J, Li JT, et al. Ragweed immunotherapy in adult asthma. N Engl J Med 1996; 334: 501–506.PubMedCrossRefGoogle Scholar
  12. Durham SR, Till SJ. Immunologic changes associated with allergen immunotherapy. J Allergy Clin Immunol 1998; 102: 157–164.PubMedCrossRefGoogle Scholar
  13. Fox RW, Lockey RF. Role of immunotherapy in asthma. In: Gershwin ME, Halpern GM, eds. Bronchial Asthma: Principles of Diagnosis and Treatment. ed. 3. Totowa, NJ, Humana Press, 1994, pp 365–398.CrossRefGoogle Scholar
  14. Joint Task Force on Practice Parameters. Practice parameters for allergen immunotherapy. J Allergy Clin Immunol 1996; 98: 1001–1011.CrossRefGoogle Scholar
  15. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST) [see comments]. J Allergy Clin Immunol 1987; 79: 660–667.PubMedCrossRefGoogle Scholar
  16. Naclerio RM, Proud D, Moylan B, Balcer S, Friedhoff L, Kagey-Sobotka A, Lichtenstein LM, Creticos PS, Hamilton RG, Norman PS, et al. Clinical aspects of allergic disease. A double-blind study of the discontinuation of ragweed immunotherapy. J Allergy Clin Immunol 1997; 100: 293–300.PubMedCrossRefGoogle Scholar
  17. Norman PS. Immunotherapy: Past and present. J Allergy Clin Immunol 1998; 102: 1–10.PubMedCrossRefGoogle Scholar
  18. Platts-Mills TAE, Chapman MD. Allergen standardization. J Allergy Clin Immunol 1991; 621–624.Google Scholar
  19. Platts-Mills TAE, Mueller GA, Wheatley LM. Future directions for allergen immunotherapy. J Allergy Clin Immunol 1998; 102: 335–343.PubMedCrossRefGoogle Scholar
  20. Stewart GE, Lockey RF. Systemic reactions from immunotherapy. J Allergy Clin Immunol 1992; 90: 567–578.PubMedCrossRefGoogle Scholar
  21. Van Metre TE, Adkinson NF. Immunotherapy for aeroallergen disease. In: Middleton E, Reed CE, Ellis EF, et al., eds. Allergy Principles and Practices, ed. 4. Baltimore, Mosby, 1997, 1489–1506.Google Scholar

Copyright information

© Springer Science+Business Media New York 2000

Authors and Affiliations

  • Roger W. Fox
  • Richard F. Lockey

There are no affiliations available

Personalised recommendations